DR. THOMAS CHRISTIAN WESSEL, MD, PHD
Medical Practice at Cliffwood St, Lenox, MA
License number
Massachusetts 184967
Category
Medical Practice
Type
Research Study
Address
Address
22 Cliffwood St, Lenox, MA 01240
Phone
(413) 464-1047
Professional information
Dr. Thomas C Wessel, Lenox MA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
22 Cliffwood St, Lenox 01240
(413) 464-1047 (Phone)
(413) 464-1047 (Phone)
Certifications:
Neurology, 1992
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Ludwig Maximiliams University / Medical Faculty
St Vincent Hosp-U Mass Sch Med
Ny Hosp-Meml Sloan-Kettering Cancer Ctr
Cornell U
Ludwig Maximiliams University / Medical Faculty
St Vincent Hosp-U Mass Sch Med
Ny Hosp-Meml Sloan-Kettering Cancer Ctr
Cornell U
Combinations Of Eszopiclone And O-Desmethylvenlafaxine, And Methods Of Treatment Of Menopause And Mood, Anxiety, And Cognitive Disorders
US Patent:
2009011, Apr 30, 2009
Filed:
Jul 5, 2006
Appl. No.:
11/994638
Inventors:
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Karim Lalji - West Vancouver, CA
Mark A. Varney - Laguna Niguel CA, US
Thomas Wessel - Lenox MA, US
Karim Lalji - West Vancouver, CA
Mark A. Varney - Laguna Niguel CA, US
Assignee:
SEPRACOR INC. - Marlborough MA
International Classification:
A61K 31/4985
US Classification:
514250
Abstract:
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
Combinations Of Eszopiclone And Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine Or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, And Methods Of Treatment Of Menopause And Mood, Anxiety, And Cognitive Disorders
US Patent:
2013006, Mar 14, 2013
Filed:
Nov 9, 2012
Appl. No.:
13/673076
Inventors:
Thomas WESSEL - Lenox MA, US
Karim LALJI - West Vancouver, CA
Mark VARNEY - Laguna Niguel CA, US
Roger P. BAKALE - Malvern PA, US
Surendra P. SINGH - Shrewsbury MA, US
H. Scott WILKINSON - Westborough MA, US
Xiping SU - Woodbridge CT, US
Zhengxu HAN - Shrewsbury MA, US
Stefan G. KOENIG - Shrewsbury MA, US
Karim LALJI - West Vancouver, CA
Mark VARNEY - Laguna Niguel CA, US
Roger P. BAKALE - Malvern PA, US
Surendra P. SINGH - Shrewsbury MA, US
H. Scott WILKINSON - Westborough MA, US
Xiping SU - Woodbridge CT, US
Zhengxu HAN - Shrewsbury MA, US
Stefan G. KOENIG - Shrewsbury MA, US
Assignee:
SUNOVION PHARMACEUTICALS INC. - Marlborough MA
International Classification:
A61K 31/4985, A61P 25/00, A61P 25/16, A61P 25/24, A61P 25/28, A61P 15/12, A61P 25/22
US Classification:
514249
Abstract:
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
Combination Of Sedative And A Neurotransmitter Modulator, And Methods For Improving Sleep Quality And Treating Depression
US Patent:
2005017, Aug 11, 2005
Filed:
Dec 8, 2004
Appl. No.:
11/007795
Inventors:
Karim Lalji - Sudbury MA, US
Timothy Barberich - Concord MA, US
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Timothy Barberich - Concord MA, US
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Assignee:
Sepracor, Inc. - Marlborough MA
International Classification:
A61K031/724, A61K031/137, A61K031/495
US Classification:
514058000, 514649000, 514469000
Abstract:
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HTmodulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HTmodulator or DRI.
Combination Of Sedative And A Neurotransmitter Modulator, And Methods For Improving Sleep Quality And Treating Depression
US Patent:
8097625, Jan 17, 2012
Filed:
Jun 11, 2007
Appl. No.:
11/761235
Inventors:
Karim Lalji - Sudbury MA, US
Timothy J. Barberich - Concord MA, US
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Timothy J. Barberich - Concord MA, US
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Assignee:
Sunovion Pharmaceuticals Inc. - Marlborough MA
International Classification:
A01N 43/58, A01N 43/40, A61K 31/50, A61K 31/497, A61K 31/435
US Classification:
514247, 5142521, 514277, 514449, 514461
Abstract:
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e. g. , insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HTmodulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HTmodulator or DRI.
Combinations Of Eszopiclone And Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine Or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, And Methods Of Treatment Of Menopause And Mood, Anxiety, And Cognitive Disorders
US Patent:
2008029, Nov 27, 2008
Filed:
Jul 6, 2006
Appl. No.:
11/994644
Inventors:
Judy Caron - Westwood MA, US
Thomas Wessel - Lenox MA, US
Karim Lalji - West Vancouver, CA
Mark A. Varney - Laguna Niguel CA, US
Roger P. Bakale - Downingtown PA, US
Surendra P. Singh - Shrewsbury MA, US
H. Scott Wilkinson - Westborough MA, US
Xiping Su - Woodbridge CT, US
Zhengxu Steve Han - Shrewsbury MA, US
Stefan G. Koenig - Shrewsbury MA, US
Thomas Wessel - Lenox MA, US
Karim Lalji - West Vancouver, CA
Mark A. Varney - Laguna Niguel CA, US
Roger P. Bakale - Downingtown PA, US
Surendra P. Singh - Shrewsbury MA, US
H. Scott Wilkinson - Westborough MA, US
Xiping Su - Woodbridge CT, US
Zhengxu Steve Han - Shrewsbury MA, US
Stefan G. Koenig - Shrewsbury MA, US
Assignee:
SEPRACOR INC. - Marlborough MA
International Classification:
A61K 31/498, C07C 209/22, A61P 25/00
US Classification:
514249, 564308
Abstract:
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
Use Of 4-Aminopyridine To Improve Neuro-Cognitive And/Or Neuro-Psychiatric Impairment In Patients With Demyelinating And Other Nervous System Conditions
US Patent:
2013005, Feb 28, 2013
Filed:
Aug 11, 2010
Appl. No.:
13/390076
Inventors:
Thomas C. Wessel - Lenox MA, US
Andrew R. Blight - Mahopac NY, US
Andrew R. Blight - Mahopac NY, US
International Classification:
A61K 31/4409, C07D 213/73, A61P 25/00
US Classification:
514352, 546311
Abstract:
Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.
Use Of Potassium Channel Blockers To Treat Cerebral Palsy
US Patent:
2013003, Jan 31, 2013
Filed:
Jan 27, 2012
Appl. No.:
13/360621
Inventors:
Thomas C. Wessel - Lenox MA, US
Adrian L. Rabinowicz - Florham Park NJ, US
Jacob D. Runyan - New Milford CT, US
Anthony Caggiano - Larchmont NY, US
Andrew Blight - Mahopac NY, US
Adrian L. Rabinowicz - Florham Park NJ, US
Jacob D. Runyan - New Milford CT, US
Anthony Caggiano - Larchmont NY, US
Andrew Blight - Mahopac NY, US
International Classification:
A61K 31/4409, A61P 25/14, A61P 25/00, A61P 21/00, A61K 31/4406, A61K 31/44
US Classification:
514352
Abstract:
Disclosed herein is the use of aminopyridines, such as 3-aminopyridine, 4-aminopyridine or 3,4-diaminopyridine, in the management and treatment of cerebral palsy patients of all ages.
Methods Of Treatment Of Chronic Pain Using Eszopiclone
US Patent:
8247417, Aug 21, 2012
Filed:
Oct 12, 2011
Appl. No.:
13/271825
Inventors:
Thomas Wessel - Lenox MA, US
Judy Caron - Westwood MA, US
Judy Caron - Westwood MA, US
Assignee:
Sunovion Pharmaceuticals Inc. - Marlborough MA
International Classification:
A61K 31/498
US Classification:
514249
Abstract:
The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
Methods Of Treatment Of Chronic Pain Using Eszopiclone
US Patent:
7776858, Aug 17, 2010
Filed:
Apr 5, 2005
Appl. No.:
11/099078
Inventors:
Thomas Wessel - Lenox MA, US
Judy Caron - Westwood MA, US
Judy Caron - Westwood MA, US
Assignee:
Sepracor Inc. - Marlborough MA
International Classification:
A61K 31/498
US Classification:
514249
Abstract:
The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.